CN103167881B - 用于抑制hiv传播的方法和组合物 - Google Patents

用于抑制hiv传播的方法和组合物 Download PDF

Info

Publication number
CN103167881B
CN103167881B CN201180028300.5A CN201180028300A CN103167881B CN 103167881 B CN103167881 B CN 103167881B CN 201180028300 A CN201180028300 A CN 201180028300A CN 103167881 B CN103167881 B CN 103167881B
Authority
CN
China
Prior art keywords
hiv
clade
env
colostrum
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180028300.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103167881A (zh
Inventor
G.T.罗林
D.F.J.普塞尔
R.J.森特
M.克拉姆斯基
- 布朗 R.M.罗宾斯
G.里奇蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center Robert John
D F Purcell
Kramski Marit
Rose Technology Co ltd
University of Melbourne
Immuron Ltd
Original Assignee
Reeve Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reeve Pharmaceutical Co Ltd filed Critical Reeve Pharmaceutical Co Ltd
Publication of CN103167881A publication Critical patent/CN103167881A/zh
Application granted granted Critical
Publication of CN103167881B publication Critical patent/CN103167881B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201180028300.5A 2010-04-09 2011-04-11 用于抑制hiv传播的方法和组合物 Expired - Fee Related CN103167881B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
US61/322399 2010-04-09
US61/322,399 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (2)

Publication Number Publication Date
CN103167881A CN103167881A (zh) 2013-06-19
CN103167881B true CN103167881B (zh) 2017-06-16

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180028300.5A Expired - Fee Related CN103167881B (zh) 2010-04-09 2011-04-11 用于抑制hiv传播的方法和组合物

Country Status (12)

Country Link
US (1) US20130022619A1 (https=)
EP (1) EP2555798B1 (https=)
JP (1) JP6026402B2 (https=)
CN (1) CN103167881B (https=)
AP (1) AP3469A (https=)
AU (2) AU2011238431B2 (https=)
BR (1) BR112012025678A2 (https=)
CA (1) CA2795853A1 (https=)
MX (1) MX343505B (https=)
RU (1) RU2594249C2 (https=)
WO (1) WO2011123900A1 (https=)
ZA (1) ZA201207790B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925471A1 (en) 2013-09-27 2015-04-02 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
AU2016326738B2 (en) * 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
WO2017062069A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless spring torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
AU2021289612A1 (en) * 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2022241058A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
EP4619430A1 (en) 2022-11-16 2025-09-24 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
CN101912610A (zh) * 1999-06-24 2010-12-15 约翰·霍普金斯大学 用于预防hiv经上皮传播的组合物和方法
ATE350015T1 (de) * 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
CA2739905A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization;Zhang P.F. et al.;《PNAS》;20070612;第104卷(第24期);摘要，结果和讨论部分，图1-3 *
P13-03. Neutralizing antibody to HIV-1 Env from hyperimmune bovine colostrum as a mucosal microbicide strategy for preventing virus transmission;Kramski M et al.;《Retrovirology》;20091022;第6卷(第3期);摘要，方法，结果和讨论部分 *

Also Published As

Publication number Publication date
RU2594249C2 (ru) 2016-08-10
RU2012142999A (ru) 2014-05-20
EP2555798A4 (en) 2013-11-20
CN103167881A (zh) 2013-06-19
MX343505B (es) 2016-11-04
BR112012025678A2 (pt) 2017-07-18
MX2012011574A (es) 2013-03-05
EP2555798A1 (en) 2013-02-13
AU2011238431A1 (en) 2012-11-08
AU2011238431B2 (en) 2016-10-06
WO2011123900A1 (en) 2011-10-13
AP3469A (en) 2015-11-30
CA2795853A1 (en) 2011-10-13
EP2555798B1 (en) 2016-06-22
US20130022619A1 (en) 2013-01-24
AP2012006519A0 (en) 2012-10-31
JP2013523783A (ja) 2013-06-17
AU2017265055A1 (en) 2019-06-06
ZA201207790B (en) 2013-06-26
JP6026402B2 (ja) 2016-11-16

Similar Documents

Publication Publication Date Title
CN103167881B (zh) 用于抑制hiv传播的方法和组合物
RU2407749C2 (ru) Иммуногенная композиция и способ разработки вакцины, основанной на слитом белке
TWI320715B (en) Improved mycoplasma hyopneumoniae bacterin vaccine
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
US7262270B2 (en) Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
EA034702B1 (ru) Липосомные композиции
Hamajima et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
CN106794336A (zh) 病毒预防性治疗方法和暴露前预防性试剂盒
Mohan et al. Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1
US20110059154A1 (en) Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CA2813612A1 (en) Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
JPH09504296A (ja) Ｈｉｖ粘膜感染の阻止
US20220257752A1 (en) New use of cyclic dinucleotides
US20200140529A1 (en) Methods and compositions for inhibiting hiv transmission
AU2021204628B2 (en) Methods and compositions related to accelerated humoral affinity
US7015016B2 (en) Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's
Zinckgraf et al. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide
Limbert Development of an Effective Chlamydial Vaccine Using Combination Adjuvants
TW202203970A (zh) 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法
Shembekar et al. Genital Mucosal Immunity Against Sexually Transmitted Infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170511

Address after: Victoria, Australia

Applicant after: Immuron Ltd.

Address before: Victoria, Australia

Applicant before: Rose Technology Co.,Ltd.

Effective date of registration: 20170511

Address after: Victoria, Australia

Applicant after: Rose Technology Co.,Ltd.

Address before: Victoria, Australia

Applicant before: Kramski Marit

Applicant before: Center Robert John

Applicant before: D. F. Purcell

Effective date of registration: 20170511

Address after: Victoria, Australia

Applicant after: Kramski Marit

Applicant after: Center Robert John

Applicant after: D. F. Purcell

Address before: Australia Melbourne

Applicant before: THE University OF MELBOURNE

Effective date of registration: 20170511

Address after: Australia Melbourne

Applicant after: THE University OF MELBOURNE

Address before: Victoria, Australia

Applicant before: Immuron Ltd.

GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170616

Termination date: 20210411